UREIDIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND THEIR USE ON THE TREATMENT OF INFLAMMATORY DISEASES

The present invention describes functionalizeds derivatives of ethyl 6-N- alkyl and/or 6-N-aryl ureas [1 ,3]dioxolo[5,4-g]quinolin-7-carboxylate (3a-z, 4a-z) and similar types (5a-z), of general formula (I, II, III and IV), useful in the treatment and/or prevention of inflammatory diseases, such as...

Full description

Saved in:
Bibliographic Details
Main Authors SPERANDIO DA SILVA, GILBERTO MARCELO, GONCALVES KOATZ, VERA LUCIA, LEGORA MACHADO, ALEXANDRE, MEDEIROS DE CARVALHO, FATIMA, MENEZES QUINTAS, LUIS EDUARDO, LACERDA BARREIRO, ELIEZER JESUS DE, MANSSOUR FRAGA, CARLOS ALBERTO, MOREIRA LIMA, LIDIA
Format Patent
LanguageEnglish
French
Published 26.04.2007
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention describes functionalizeds derivatives of ethyl 6-N- alkyl and/or 6-N-aryl ureas [1 ,3]dioxolo[5,4-g]quinolin-7-carboxylate (3a-z, 4a-z) and similar types (5a-z), of general formula (I, II, III and IV), useful in the treatment and/or prevention of inflammatory diseases, such as acute or chronic inflammatory conditions, different types of arthritis, asthma, Crohn's Disease and diabetes mellitus Type I, among others. These derivatives have the ability of modulate the inflammatory process, acting in mitogen activated protein kinase p-38 (MAPK-p38). Moreover, the derivatives of the present invention present expressive anti-inflammatory properties evaluated in in vivo models. The present invention also discloses processes for the production of such derivatives and harmaceutical com ositions containin the same. L'invention concerne des dérivés fonctionnalisés d'urées éthyl 6-N-alkyl et/ou 6-N-aryl [1,3]dioxolo[5,4-g]quinolin-7-carboxylate (3a-z, 4a-z) et de types similaires (5a-z), de formule générale (I, II, III et IV), utiles dans le traitement et/ou la prévention de maladies inflammatoires, telles que les états inflammatoires aigus ou chroniques, les différents types d'arthrite, l'asthme, la maladie de Crohn et le diabète de type 1, entre autres. Ces dérivés présentent la capacité de moduler le processus inflammatoire en agissant sur la protéine kinase activée par le mitogène p38 (MAPK-p38). De plus, les dérivés selon l'invention présentent des propriétés anti-inflammatoires expressives évaluées dans des modèles in vivo. L'invention concerne également des procédés de production de ces dérivés, ainsi que des compositions pharmaceutiques les contenant.
Bibliography:Application Number: WO2006BR00107